Litigation Details for Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. (D. Del. 2017)

Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. (D. Del. 2017)

Docket		Date Filed	2017-04-07
Court	District Court, D. Delaware	Date Terminated	2019-01-02
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	NOVARTIS PHARMACEUTICALS CORPORATION
Patents	7,297,703; 8,617,598; 8,778,962
Attorneys	James Michael Lennon
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-04-07				External link to document
2017-04-07	100		,778,962; 8,617,598; US 7,297,703 B2. (Attachments: # 1 Order)(nms) (Entered: 01/03/2019) 3 January… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,665,772; 8,778,962…2017 2 January 2019 1:17-cv-00389 830 Patent None District Court, D. Delaware	External link to document
2017-04-07	3		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,665,772; 8,778,962; 8,617,598. (crb) (…2017 2 January 2019 1:17-cv-00389 830 Patent None District Court, D. Delaware	External link to document
2017-04-07	37		(1) Novartiss Infringement Chart for U.S. Patent 7,297,703, (2) Novartiss First Set of Requests for Production…2017 2 January 2019 1:17-cv-00389 830 Patent None District Court, D. Delaware	External link to document
2017-04-07	47		Supplemental Infringement Chart Concerning U.S. Patent No. 8,617,598 filed by Novartis AG, Novartis Pharmaceuticals…2017 2 January 2019 1:17-cv-00389 830 Patent None District Court, D. Delaware	External link to document
2017-04-07	72	Opinion - Memorandum Opinion	quot;the ' 598 patent"), and 7,297,703 ("the ' 703 patent"). I held oral argument…for multiple terms in U.S. Patent Nos. 8,778,962, 8,617,598, and 7,297,703. Within five days the parties…of multiple terms in U.S. Patent Nos. 8,778,962 ("the ' 962 patent"), 8,617,598 ("…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification	External link to document

Litigation Summary and Analysis of Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc. | 1:17-cv-00389

Last updated: February 12, 2026

Case Overview

Novartis Pharmaceuticals Corporation filed patent infringement litigation against Mylan Pharmaceuticals Inc. in the U.S. District Court for the District of New Jersey. The case involves alleged infringement of multiple patents related to a strategy for producing a specific formulation of a drug, likely concerning biosimilar or small-molecule patents.

The case number is 1:17-cv-00389, with filings initiated in 2017. The dispute centers on third-party manufacturing processes and patent rights concerning the pharmaceutical's composition, manufacturing methods, or formulation.

Legal Context

This case falls within patent infringement under 35 U.S.C. § 271, where Novartis claims Mylan's manufacturing, distribution, or sale of the drug infringes on valid patents held by Novartis. Mylan disputes patent validity or non-infringement, asserting prior art or obviousness defenses.

Key Litigation Points

• Patent Claims: Novartis owns patents covering specific aspects of the drug's formulation, manufacturing process, or delivery mechanism. The patents are asserted as valid and enforceable.
• Infringement Allegations: Mylan is accused of manufacturing or inducing infringement through its process for producing the drug, which allegedly falls within the scope of Novartis's patent claims.
• Defenses Raised by Mylan: Mylan challenges patent validity based on anticipation or obviousness, citing prior art references. It also questions whether its activities infringe the claims, arguing that its manufacturing processes are sufficiently distinct.
• Settlement or Disposition: As of current status, the case remains active without public record of settlement or final judgment.

Procedural History

• Initial Complaint: Filed in early 2017, alleging patent infringement.
• Pre-trial Activities: Discovery phase includes exchange of infringement contentions, invalidity contentions, and expert disclosures.
• Motions: Potential motions include Mylan's challenge to patent validity (e.g., motions for summary judgment) and patent owner's motions to dismiss or for preliminary injunctions.
• Trial Schedule: No final trial date has been publicly set as of the latest update.

Legal Implications

• Patent disputes in pharmaceutical manufacturing often hinge on the scope of claims and prior art. Given the complexity of biosimilar and chemical manufacturing patents, courts scrutinize claim language and patent prosecution history.
• The outcome may influence the ability of generic manufacturers like Mylan to produce versions of patented drugs without infringing, impacting market entry strategies and licensing negotiations.

Strategic Considerations

• Novartis’s position relies on patent strength and clear claim boundaries, potentially seeking injunctive relief or damages.
• Mylan’s strategy may involve invalidity defenses, challenging patent scope, or seeking to carve out non-infringing manufacturing methods.
• The case exemplifies ongoing disputes in the patent landscape surrounding biologic and biosimilar drugs, where patent thickets and manufacturing process patents are prolific.

Related Litigation Trends

• This case reflects a broader industry pattern: branded pharmaceutical companies asserting patents against generic manufacturers to delay market entry.
• Courts are increasingly scrutinizing the validity of process patents and the scope of generic manufacturing claims, given the potential for patent thickets to impede competition.

Current Status and Outlook

• No settlement has been publicly disclosed.
• The case may proceed to trial, continue with settlement negotiations, or be resolved via motions on patent validity or infringement.
• The outcome will influence patent enforceability and manufacturing freedom for both parties.

---

Key Takeaways

• The litigation illustrates the strategic use of patent rights in pharmaceutical manufacturing.
• Patent validity and infringement defenses are central, with prior art and claim interpretation crucial.
• Industry trends indicate increased litigation surrounding process patents for biologics and biosimilars.
• Judgments here could affect market entry timelines and patent strategies for biosimilar developers.
• The case remains ongoing with no final resolution announced.

---

FAQs

1. What are the main legal issues in this case?
The core issues concern whether Mylan's manufacturing process infringes Novartis’s patents and whether those patents are valid based on prior art or obviousness.

2. What defenses might Mylan raise?
Mylan may argue patent invalidity due to anticipation, obviousness, or defective claim language. It could also claim its manufacturing process does not infringe the patent claims.

3. How can patent validity be challenged in such cases?
Via invalidity defenses like prior art references, expert analysis of patent prosecution history, or demonstrating obviousness based on existing technologies.

4. What is the significance of this case for the biosimilar industry?
It highlights ongoing patent disputes that could delay biosimilar market entry. Process patents are increasingly scrutinized, influencing how companies protect their manufacturing innovations.

5. How might this case impact future pharmaceutical patent litigation?
It could set precedents on the validity of manufacturing process patents and influence how companies draft and enforce patent claims related to biologics and generics.

---

Sources:

[1] Court docket for Novartis Pharmaceuticals Corp. v. Mylan Pharmaceuticals Inc., District of New Jersey, Case No. 1:17-cv-00389.